Literature DB >> 22401960

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Sagar Agarwal1, Yasuo Uchida, Rajendar K Mittapalli, Ramola Sane, Tetsuya Terasaki, William F Elmquist.   

Abstract

The objective of this study was to quantitatively examine the protein expression of relevant transporters and other proteins in the brain capillary endothelial cells isolated from wild-type mice and P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. After the isolation of brain capillary endothelial cells, a highly sensitive liquid chromatography-tandem mass spectrometry method with multiple reaction monitoring was used to determine the quantitative expression of membrane transporters at the blood-brain barrier (BBB) of the various mouse genotypes. Quantitative expression of 29 protein molecules, including 12 ATP-binding cassette transporters, 10 solute carrier transporters, five receptors, and two housekeeping proteins, was examined by quantitative proteomics in the four mouse genotypes. There was no significant difference in the expression of P-gp between the wild-type and Bcrp1(-/-) mice. Likewise, Bcrp expression was not significantly different between the wild-type and Mdr1a/b(-/-) mice. There was no significant difference in the expression of any of the measured proteins in the brain capillary endothelial cells across the genotypes, except for the lack of expression of the corresponding protein in the mice that had a genetic deletion of P-gp or Bcrp. In conclusion, using a quantitative proteomic approach, we have shown that there are no changes in the expression of several relevant transporters in brain capillary endothelial cells isolated from single and combination knockout mice. These data suggest that the mechanism behind the functional compensation between P-gp and Bcrp at the BBB is not related to compensatory changes in transporter expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22401960      PMCID: PMC3362790          DOI: 10.1124/dmd.112.044719

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

Review 1.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

Review 2.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 3.  Pharmacological insights from P-glycoprotein knockout mice.

Authors:  A H Schinkel
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

4.  Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.

Authors:  Hiroshi Uchino; Yoshikatsu Kanai; Do Kyung Kim; Michael F Wempe; Arthit Chairoungdua; Emiko Morimoto; M W Anders; Hitoshi Endou
Journal:  Mol Pharmacol       Date:  2002-04       Impact factor: 4.436

Review 5.  Multidrug resistance-associated proteins: expression and function in the central nervous system.

Authors:  Shannon Dallas; David S Miller; Reina Bendayan
Journal:  Pharmacol Rev       Date:  2006-06       Impact factor: 25.468

Review 6.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

Authors:  Alfred H Schinkel; Johan W Jonker
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

Review 7.  Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.

Authors:  B Hagenbuch; C Gui
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

8.  Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Authors:  Young-Joo Lee; Hiroyuki Kusuhara; Johan W Jonker; Alfred H Schinkel; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2004-09-24       Impact factor: 4.030

9.  P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Authors:  Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

10.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Claire Mercier; Fanchon Bourasset; Françoise Roux; Jean-Michel Scherrmann
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

View more
  40 in total

1.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 2.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

3.  Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.

Authors:  Loqman A Mohamed; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2016-01-15

4.  Diet-induced obesity suppresses expression of many proteins at the blood-brain barrier.

Authors:  Suidong Ouyang; Hung Hsuchou; Abba J Kastin; Yuping Wang; Chuanhui Yu; Weihong Pan
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-25       Impact factor: 6.200

5.  Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.

Authors:  Minjee Kim; Janice K Laramy; Gautham Gampa; Karen E Parrish; Richard Brundage; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-10-16       Impact factor: 3.922

Review 6.  Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics.

Authors:  Bhagwat Prasad; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-04-22       Impact factor: 4.009

Review 7.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

8.  Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-10-10       Impact factor: 4.030

9.  The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.

Authors:  Ramola Sane; Shu-Pei Wu; Rong Zhang; James M Gallo
Journal:  Drug Metab Dispos       Date:  2014-01-24       Impact factor: 3.922

10.  Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

Authors:  Selvi Durmus; Rolf W Sparidans; Anita van Esch; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Pharm Res       Date:  2014-06-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.